Publication List 2013

1984-94, 1995, 1996, 1997, 1998, 1999, 2000, 2001, 2002, 2003, 2004, 2005, 2006, 2007, 2008, 2009, 2010, 2011, 2012, 2013, 2014, 2015, 2016, 2017, 2018

15
(410)
Yoshimatsu Y, Lee YG, Akatsu Y, Taguchi L, Suzuki HI, Cunha SI, Maruyama K, Suzuki Y, Yamazaki T, Katsura A, Oh SP, Zimmers TA, Lee SJ, Pietras K, Koh GY, Miyazono K, Watabe T.
Bone morphogenetic protein-9 inhibits lymphatic vessel formation via activin receptor-like kinase 1 during development and cancer progression.
Proc Natl Acad Sci U S A. 2013 Nov 19;110(47):18940-5.
14
(409)
Kasuga M, Ueki K, Tajima N, Noda M, Ohashi K, Noto H, Goto A, Ogawa W, Sakai R, Tsugane S, Hamajima N, Nakagama H, Tajima K, Miyazono K, Imai K.
Report of the Japan Diabetes Society/Japanese Cancer Association Joint Committee on Diabetes and Cancer.
Cancer Sci. 2013 Jul;104(7):965-76.
13
(408)
Fukumura K, Yamashita Y, Kawazu M, Sai E, Fujiwara S, Nakamura N, Takeuchi K, Ando M, Miyazono K, Ueno T, Ozawa K, Mano H.
STK10 missense mutations associated with anti-apoptotic function.
Oncol Rep. 2013 Oct;30(4):1542-8.
12
(407)
Shirakihara T, Kawasaki T, Fukagawa A, Semba K, Sakai R, Miyazono K, Miyazawa K, Saitoh M.
Identification of integrin α3 as a molecular marker of cells undergoing epithelial-mesenchymal transition and of cancer cells with aggressive phenotypes.
Cancer Sci. 2013 Sep;104(9):1189-97.
11
(406)
Ehata S, Yokoyama Y, Takahashi K, Miyazono K.
Bi-directional roles of bone morphogenetic proteins in cancer: another molecular Jekyll and Hyde?
Pathol Int. 2013 Jun;63(6):287-96.
10
(405)
Konoeda C, Koinuma D, Morishita Y, Sano A, Nagayama K, Motomura N, Kakimi K, Miyazono K, Nakajima J, Nicolls MR, Murakawa T.
Epithelial to mesenchymal transition in murine tracheal allotransplantation: an immunohistochemical observation.
Transplant Proc. 2013 Jun;45(5):1797-801.
9
(404)
Motizuki M, Isogaya K, Miyake K, Ikushima H, Kubota T, Miyazono K, Saitoh M, Miyazawa K.
Oligodendrocyte transcription factor 1 (Olig1) is a Smad cofactor involved in cell motility induced by transforming growth factor-β.
J Biol Chem. 2013 Jun 28;288(26):18911-22.
8
(403)
Saitoh M, Shirakihara T, Fukasawa A, Horiguchi K, Sakamoto K, Sugiya H, Beppu H, Fujita Y, Morita I, Miyazono K, Miyazawa K.
Basolateral BMP signaling in polarized epithelial cells.
PLoS One. 2013 May 13;8(5):e62659.
7
(402)
Suzuki HI, Matsuyama H, Noguchi M, Yao T, Komatsu N, Mano H, Sugimoto K, Miyazono K.
Computational dissection of distinct microRNA activity signatures associated with peripheral T cell lymphoma subtypes.
Leukemia. 2013 Oct;27(10):2107-11.
6
(401)
Yamazaki T, Suehiro J, Miyazaki H, Minami T, Kodama T, Miyazono K, Watabe T.
The COUP-TFII variant lacking a DNA-binding domain inhibits the activation of the Cyp7a1 promoter through physical interaction with COUP-TFII.
Biochem J. 2013 Jun 1;452(2):345-57.
5
(400)
Suzuki HI, Mihira H, Watabe T, Sugimoto K, Miyazono K.
Widespread inference of weighted microRNA-mediated gene regulation in cancer transcriptome analysis.
Nucleic Acids Res. 2013 Mar 1;41(5):e62.
4
(399)
Kawabata KC, Ehata S, Komuro A, Takeuchi K, Miyazono K.
TGF-β-induced apoptosis of B-cell lymphoma Ramos cells through reduction of MS4A1/CD20.
Oncogene. 2013 Apr 18;32(16):2096-106.
3
(398)
Suzuki HI, Miyazono K.
p53 actions on microRNA expression and maturation pathway.
Methods Mol Biol. 2013;962:165-81.
2
(397)
Sundqvist A, Zieba A, Vasilaki E, Herrera Hidalgo C, Söderberg O, Koinuma D, Miyazono K, Heldin CH, Landegren U, Ten Dijke P, van Dam H.
Specific interactions between Smad proteins and AP-1 components determine TGFβ-induced breast cancer cell invasion.
Oncogene. 2013 Aug 1;32(31):3606-15.
1
(396)
Morikawa M, Koinuma D, Miyazono K, Heldin CH.
Genome-wide mechanisms of Smad binding.
Oncogene. 2013 Mar 28;32(13):1609-15.